Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEGEAN
NCT01884350Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2013
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 4, randomised, open-label trial of apixaban in Atrial fibrillation (AFib) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen at 24 weeks. Started Oct 2013; status: completed.
02
Drugs
apixaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT01884350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01884350.